Detecting Cancer Cells and DNA in Blood, Urine and Bone Marrow
Collects blood, urine and bone marrow samples from adults with solid cancers.
Key facts
- Who runs it
- University of Missouri-Columbia
- Where
- Columbia, United StatesSee the site
- Trial code
- Registry title
- Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- Status
- Recruiting
- People taking part
- 620 people, planned
- Started
- 1 Jul 2016
- Expected to end
- 1 Dec 2027
- Type of study
- Observational
- Treatments tested
- Study sample collection
- Record updated
- 1 May 2026
Who can take part
The trial is looking for adults with a solid cancer of any stage, such as lung, esophageal, stomach, bile duct, pancreas or colorectal cancer, melanoma or sarcoma. Adults with no cancer who have surgery for a benign reason can join as controls.
- Age
- Older than 18 years.
- Sex
- All genders can join.
- Disease stage
- A solid cancer of any stage (lung, esophageal, stomach, bile duct/pancreas, colorectal, melanoma, sarcoma).
- Main reasons for not taking part
- Pregnant women.
- Another active cancer besides basal cell skin cancer, if there is evidence of disease or current chemotherapy.
- Hemoglobin below 8g/dl on the morning of the procedure.
- Needing more than 4 units of red packed blood cells during surgery: no further blood is drawn for the study analysis.
- Bleeding disorders that need prophylactic clotting products: no bone marrow aspiration is done.
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Subjects older than 18 years
- Subjects of all genders and ethnicities
- Subjects with the diagnosis of a solid cancer (n=100) of all stages will be included (lung, esophageal, stomach, bile duct/pancreas, colorectal, melanoma, sarcoma)
- Ten patients with no present suspicion and no previous history of any cancer (except basal cell cancer of the skin) that undergo surgeries for other benign indications will serve as controls (n=20)
- In patients undergoing surgery for cancer the histopathology should preferably be pathologically proven by a previous or novel biopsy. Yet, patients with a high cancer suspicion by radiology and clinical picture that undergo cancer surgery will not be excluded. No additional biopsies, testing or interventions will be performed for the purpose of this study if the medical treatment will not require it
- Subjects must be capable of giving informed consent
Who cannot take part
- Subjects with the concurrent diagnosis of an active secondary (synchronous) malignancy besides basal cell carcinoma of the skin will be excluded, if there is evidence of disease burden or if the patient is currently being treated with chemotherapy
- In subjects who require intraoperative transfusions of >4 units of red packed blood cells (RPBCs), no further blood will be drawn for CTC/DTC/cfDNA analysis during surgery or on postoperative day 1
- In patients with coagulation disorders that could lead to significant bleeding (such as hemophilia, significant thrombocytopenia) requiring prophylactic administration of coagulative products, no bone marrow aspiration will be performed
- Subjects with a hemoglobin of <8g/dl in the morning of the procedure will be excluded
- Pregnant women
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in United States.
- Ellis Fischel Cancer Center, University of MissouriColumbia, United StatesContact: Jussuf T Kaifi, MD, PhDTaking people
About the trial
What the trial wants to find out
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized therapies.
The group in the trial
- Study sample collection
Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- Plain-language title
- Detecting Cancer Cells and DNA in Blood, Urine and Bone MarrowGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT02838836, who can take part
- Publications
- Record updated
- 1 May 2026